20th Annual Pain Medicine Meeting

“Pain 2021: A Whole New World”

November 18-20, 2021 | San Francisco, CA, and Virtually

Abstracts - ePosters

 


Important Dates

Abstract Submission Deadline (no extensions):

Thursday, August 26 (11:59 pm ET)

Abstract Notifications Sent: 

Monday, September 20

Early-Bird Registration Cut-Off: 

Thursday, October 7

ePoster Submission Deadline (no extensions): 

Thursday, October 14 (11:59 pm ET)

Final Confirmation Letters Sent with Session Assignments:

Monday, October 18

 


 

Best of Meeting Abstracts

2292

CAN A PROTOCOL REPLACE MANDATORY PSYCHOLOGICAL ASSESSMENT FOR WORKUP OF NEUROMODULATION THERAPIES FOR PAIN?
Maggie Xiao, Fung Ping Wong, Amol Deshpande, Anuj Bhatia, Hemkumar Pushparaj, Kathryn Curtis, Pranab Kumar, Jamal Kara
Toronto Western Hospital, Toronto, Canada
Podium Presentation: Thursday, 1:30-1:35 pm, Refresher Course Spinal Cord Stimulation: Excellent Tool for the Right Patient

2369

ULTRASOUND CHARACTERISTICS OF A NEW PROLONGED DRUG DELIVERY MATRIX FOR PERIPHERAL NERVE BLOCK
Matt Purcell, William Taylor, Kelsey Pflepsen, Mark Ereth
Mayo Clinic College of Medicine and Science, Rochester, MN
Podium Presentation: Thursday, 10:00-10:05 am, Refresher Course Headaches Management: An Updated Reality

2505

APPLIED ANATOMY OF WRIST INNERVATION RELEVANT TO ULTRASOUND GUIDED INTERVENTION FOR CHRONIC WRIST PAIN
Loretta TS Ho, John Tran, Anne MR Agur, Philip WH Peng
University of Toronto, Toronto, Canada
Podium Presentation: Thursday, 8:15-8:20 am, Refresher Course Neuropathic Pain: Overview of the Current Treatment and Future Therapeutic Approaches

 

Resident/Fellow Travel Awards

2160

EFFECT OF PATIENT CHARACTERISTICS ON CLINICAL OUTCOMES OVER 12 MONTHS FOLLOWING DORSAL ROOT GANGLION STIMULATION IMPLANTATION
Abhishek Yadav, Jonathan Hagedorn, Timothy Deer, Ian McArdle, Ryan D'Souza
Brown University, Providence, RI
Podium Presentation: Friday, 8:00-8:05 am, PS-01a Chronic Back Pain in Non-Surgical Candidate

2229

RACIAL AND SOCIOECONOMIC DISPARITIES IN KYPHOPLASTY AMONG THE MEDICARE POPULATION
Mark Jones, Joseph Manzi, Frank Chen, Ethan Brovman, Nikhilesh Rao, Stephanie Vanterpool, Richard Urman
Pain Medicine of the South, Knoxville, TN
Podium Presentation: Friday, 1:45-1:50 pm, PS-03a Advancement in the Field of Peripheral Nerve Stimulation: Lessons Learned

2299

DEXAMETHASONE EFFECTIVELY REDUCES THE INCIDENCE OF POST-NEUROTOMY NEUROPATHIC PAIN: A RANDOMIZED CONTROLLED PILOT STUDY
Alexander Shustorovich, Tariq AlFarra, Aaron T. Arel, Jaspal R. Singh, Ryan T. Roemmich, Akhil Chhatre
University of California San Diego Medical Center, La Jolla, CA
Podium Presentation:  Friday, 8:00-8:05 am, PS-01b Updates on Cancer Pain Management

 


President's Choice

2172

MRI FOR IN VIVO ANALYSIS OF ABLATION ZONES FORMED BY COOLED RADIOFREQUENCY NEUROTOMY ACROSS MULTIPLE AXIAL SPINE SITES
Mehul Desai, Yair Safriel
Avanos Medical, Alpharetta, GA
Podium Presentation: Friday, 10:30-10:35 am, PS-02a Parallel Session Radiofrequency Ablation: Current Evidence for Spine and Joint Pain

2215

THE EFFECT OF VIRTUAL REALITY ON PAIN AND PATIENT SATISFACTION IN ADULTS RECEIVING GENICULAR NERVE RADIOFREQUENCY ABLATION
Brent Etiz, Hailey Maxwell, Brent Yeung, Shalini Shah, Navid Alem
University of California, Irvine, School of Medicine, Irvine, CA
Podium Presentation: Saturday, 8:00-8:05 am, Plen-01 Plenary Session Disruptive, Constructive, or Destructive Innovations

2283

VIRTUAL REALITY IN THE TREATMENT OF PAIN AND/OR DEPRESSION IN CHILDREN
Kristy Fisher, Samantha Scemla, Brianna Cocuzzo, Christian Gonzalez, Jacqueline Horan Fisher
HCA Aventura Hospital and Medical Center, Aventura, FL
Podium Presentation: Friday, 10:30-10:35 am, PS-02b Parallel Session Chronic Pain in Pediatrics: Current Science and Integrative Practice

2348

PROSPECTIVE, MULTICENTER STUDY OF PERCUTANEOUS MEDIAL BRANCH PNS FOR THE TREATMENT OF CHRONIC AXIAL LOW BACK PAIN
Christopher Gilmore, Mehul Desai, Thomas Hopkins, Sean Li, Michael DePalma, Timothy Deer, Steven Cohen
SPR Therapeutics, Cleveland, OH
Podium Presentation: Saturday, 2:15-2:20 pm, Plen-03 Plenary Session A Whole New World: National Crisis and Bias Impact on Chronic Pain Practice

2457

LONG-TERM HIGH-FREQUENCY (10 KHZ) SPINAL CORD STIMULATION IN PAINFUL DIABETIC NEUROPATHY - A RANDOMIZED CONTROLLED TRIAL
Erika Petersen, Thomas Stauss, James Scowcroft, Judith White, Shawn Sills, Kasra Amirdelfan, Maged Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis Patterson, Vincent Galan, Richard Bundschu, Neel Mehta, Dawood Sayed, Shivanand Lad, David DiBenedetto, Nagy Mekhai
Nevro Corp., Redwood City, CA
Podium Presentation: Thursday, 3:45-3:50 pm, RC-04 Refresher Course: Beyond Opioid Crisis: Lessons Learned and Need for Alternatives

2482

CHARACTERIZATION OF DIFFERENT ENERGY PROFILES OF DIFFERENTIAL TARGET MULTIPLEXED™ SPINAL CORD STIMULATION
David Provenzano, Michael Fishman, John Hatheway, Andrew Will, Binit Shah, Gobi Paramanandam, Kasra Amirdelfan, Michael Esposito, Kliment Gatzinsky, Prabhdeep Grewal, Jan Willem Kallewaard
Medtronic, Minneapolis, MN
Podium Presentation: Friday, 1:45-1:50 pm, PS-03b Parallel Session Translating Chronic Pain Research Into Practice

2488

LONG-TERM OUTCOMES USING AN SCS SYSTEM CAPABLE OF COMBINATION THERAPY FOR CHRONIC PAIN: A RANDOMIZED CONTROLLED TRIAL (COMBO)
Mark Wallace, James North, Gregory Phillips, Duane Griffith, James Scowcroft, Bindu Popat-Lewis, Jennifer Lee, Edward Washabaugh, Julio Paez, Robert Bolash, John Noles, Joseph Atallah, Binit Shah, Farshad Ahadian, Drew Trainor
Boston Scientific, Valencia, CA
Podium Presentation: Saturday, 10:45-10:50 am, Plen-02 Plenary Session Risk Mitigation and Complication Management for Best Practice

2566

SPINAL CORD STIMULATION AT 10KHZ FOR NON-SURGICAL REFRACTORY BACK PAIN: RCT SIX-MONTH RESULTS WITH OBJECTIVE FUNCTIONAL OUTCOME
Leonardo Kapural, Jessica Jameson, Naresh Patel, Curtis Johnson, Daniel Kloster, Aaron Calodney, Peter Kosek, Julie Pilitsis, Markus Bendel, Erika Petersen, Chengyuan Wu, Taissa Cherry, Shivanand Lad, Cong Yu, Dawood Sayed, Jonathan Goree, Mark Lyons, Andrew Sack, Diana Bruce
Nevro Corp., Redwood City, CA
Podium Presentation: Friday, 4:15-4:20 pm, PS-04a Parallel Session Regenerative Medicine: What Has Worked and Where is the Evidence?

2183

PREVALENCE OF STAPHYLOCOCCUS AUREUS COLONIZATION IN SPINAL CORD STIMULATOR PATIENTS
David Provenzano, David Provenzano, Alex Keith, Jason Kilgore
Pain Diagnostics and Interventional Care, Sewickley, PA
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04a

2193

THE NEED FOR MORE PAIN MEDICINE APPLICANTS: AN EVALUATION OF THE NATIONAL RESIDENT MATCHING PROGRAM FROM 2014 TO 2020
Daniel Vanzant, Daniel Vanzant, Taif Mukhdomi, Junaid Mukhdomi, Marcus Harris, Shrif Costandi
Cleveland Clinic, Cleveland, OH
Moderated ePoster: Saturday, 2:15-4:30 pm, Moderated Session MP-11b

2280

DOES BUPIVACAINE IMPROVE PAIN IN AN INTRATHECAL PUMP POPULATION UTILIZING A LOW-DOSE STRATEGY
Nathan Abdelsayed, Nathan Abdelsayed, Jay Grider, Rachana Pasupleti, Dalia Antebi-Lerman, Michael Harned
University of Kentucky, Lexington, KY
Moderated ePoster: Friday, 1:45-3:30 pm, Moderated Session MP-07b

2339

RADIATION USE TRENDS DURING SPINAL CORD STIMULATOR PLACEMENT PERFORMED BY FELLOW TRAINEES
Ross Barman, Ryan D'Souza, Oludare Olatoye
Mayo Clinic, Rochester, MN
Moderated ePoster: Thursday, 10:00am-12:00 pm, Moderated Session MP-02a

2350

REAL WORLD EVIDENCE OF SUSTAINED IMPROVEMENTS FOLLOWING PERCUTANEOUS PNS: A CROSS-SECTIONAL FOLLOW-UP SURVEY OF 354 PATIENTS
Nate Crosby, Matthew Pingree, Mark Hurdle, David Spinner, Ali Valimahomed, Nate Crosby, Joseph Boggs
SPR Therapeutics, Durham, NC
Moderated ePoster: Thursday, 1:30-3:30 pm, Moderated Session MP-03b

2351

60-DAY PNS TREATMENT MAY IMPROVE IDENTIFICATION OF FALSE-POSITIVE AND FALSE-NEGATIVE RESPONDERS
Nate Crosby, Ramana Naidu, Sean Li, Mehul Desai, Samir Sheth, Nate Crosby, Joseph Boggs
SPR Therapeutics, Durham, NC
Moderated ePoster: Thursday, 1:30-3:30 pm, Moderated Session MP-03b

2368

ACUTE TO CHRONIC PAIN SIGNATURES (A2CPS) PROGRAM: MULTIDISCIPLINARY PAIN SCIENCE IN AN AGE OF BIODISCOVERY
Chad M. Brummett, Chad M. Brummett, Asokumar Buvanendran, Tessa Balach, John W. Burns, Joshua J. Jacobs, Robert J. McCarthy, Richard Wixson, Xiaohong Joe Zhou, Kumari Adams, Andrew Chang, Daniel Clauw, Mark DeLano, Richard E. Harris, Steven Harte, Tanja Jovanovic, Andrew Popoff, Jennifer Waljee, Robert Welsh, David Williams, Brian Caffo, Ari Kahn, Martin A. Lindquist, Stephani P. Sutherland, Tor D. Wager, Emine Bayman, Giovanni Berardi, Christopher Coffey, Dana L. Dailey, Dixie Ecklund, Laura Frey-Law, Kathleen A. Sluka, Carol G.T. Vance, Kathleen Fisch, Timothy Howard, Jon Jacobs, Kristen Jepsen, Carl D. Langefeld, Louise Laurent, Anna Lokshin, Michael Olivier, Wei-Jun Qian, Cheryse Sankar, Laura Wandner, and the A2CPS Consortium
University of Michigan School of Medicine, Ann Arbor, MI
Moderated ePoster: Thursday, 10:00am-12:00 pm, Moderated Session MP-02a

2370

SHORT TERM EFFICACY OF INTERSPINOUS SPACER INSERTION IN LUMBAR SPINAL STENOSIS: A SINGLE-CENTER, INDEPENDENT, RETROSPECTIVE REVIEW
Austin Reilly, Austin Reilly, Milad Francis, Henry Guan, Magdalena Anitescu
University of Chicago Medicine, Chicago, IL
Moderated ePoster: Thursday, 1:30-3:30 pm, Moderated Session MP-03b

2405

A MULTIDISCIPLINARY TRANSITIONAL PAIN SERVICE IS ASSOCIATED WITH REDUCED OPIOID DEPENDENCE AFTER PRIMARY TOTAL JOINT ARTHROPLASTY
Kimberlee Bayless, Joseph Featherall, Joshua Anderson, Lucas Anderson, Kimberlee Bayless, Zachary Anderson, Benjamin Brooke, Michael Buys
Veterans Affairs Medical Center, Salt Lake City, UT
Moderated ePoster: Friday, 8:00-9:45 am, Moderated Session MP-05b

2412

CHARACTERIZATION OF NON-SURGICAL BACK PAIN WITHIN THE DIFFERENTIAL TARGET MULTIPLEXED SCS RANDOMIZED CONTROLLED STUDY
David Cedeno, Michael Fishman, Harold Cordner, Rafael Justiz, Binit Shah, Philip Kim, Aaron Calodney, Mahendra Sanapati, Ye Tan, Ricardo Vallejo
SGX Medical, Bloomington, IL
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04a

2418

A RANDOMIZED CONTROLLED TRIAL EVALUATING DIFFERENTIAL TARGET MULTIPLEXED SCS FOR INTRACTABLE CHRONIC LOW BACK PAIN WITH LEG PAIN
David Cedeno, Michael Fishman, Harold Cordner, Rafael Justiz, David Provenzano, Binit Shah, Christopher Merrell, Julian Naranjo, Philip Kim, Aaron Calodney, Jonathan Carlson, Richard Bundschu, Mahendra Sanapati, Vipul Mangal, Ricardo Vallejo
SGX Medical, Bloomington, IL
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04a

2463

INFECTION AFTER SPINAL CORD STIMULATOR TRIALS: A RETROSPECTIVE REVIEW
Muhammad Mubashir, Muhammad Mubashir, Nasir Hussain, Rana Al-Jumah, Jatinder Gill, Tristan Weaver, Thomas Simopoulos
Beth Israel Deaconess Medical Center, Boston, MA
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04b

2474

NEUROMONITORING PROTOCOLS FOR PERCUTANEOUS SPINAL CORD STIMULATOR LEAD PLACEMENT
Nathan Yu, Amberly Orr, Nathan Yu, Sandra Rose, Jaleesia Green, Magdalena Anitescu
University of Chicago, Chicago, IL
Moderated ePoster: Friday, 8:00-9:45 am, Moderated Session MP-05b

2490

EFFECTIVENESS OF CANNABINOID-BASED MEDICINES BY PAIN MECHANISM AND FORMULATION: REAL-WORLD DATA TO ADDRESS AN UNDERSTUDIED FIELD
Maria Fernanda Arboleda, Maria Fernanda Arboleda, Lucile Rapin, Erin Prosk, Michael Dworkind
Santé Cannabis, Mexico City, Mexico
Moderated ePoster: Poster Only

2492

INCREASED SPINAL CORD STIMULATION (SCS) TRIAL EFFICIENCY & PAIN RELIEF USING NEURAL DOSING AND PRECISE SUB-PERCEPTION TARGETING
Roshini Jain, Richard Ferro, Lilly Chen, Roshini Jain
Boston Scientific, Valencia, CA
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04b

2494

LONG-TERM PAIN RELIEF USING AN SCS DEVICE CAPABLE OF SIMULTANEOUS COMBINATION THERAPY AND DORSAL HORN MODULATION
Roshini Jain, Clark Metzger, M. Blake Hammond, Stephen Pyles, Edward Washabaugh, Romanth Waghmarae, Anthony Berg, James North, Yu Pei, Roshini Jain
Boston Scientific, Valencia, CA
Moderated ePoster: Thursday, 3:45-5:15 pm, Moderated Session MP-04b

2581

REAL-WORLD STUDY OF INTRANASAL KETAMINE FOR USE IN PATIENTS WITH REFRACTORY CHRONIC MIGRAINE
Hsiangkuo Yuan, Hsiangkuo Yuan, Clinton Laurtsen, Eugene Viscusi, Michael Marmura
Thomas Jefferson University, Philadelphia, PA
Moderated ePoster: Friday, 8:00-9:45 am, Moderated Session MP-05a

2606

THE INCIDENCE OF SPINAL CORD INJURY AFTER SPINAL CORD STIMULATOR IMPLANT: AN UPDATED RETROSPECTIVE REVIEW
Nasir Hussain, Nasir Hussain, Mubashir Muhammad, Thomas Simopoulos, Tristan Weaver, Robert Schroell, Alaa Abd-Elsayed, Jatinder Gill
Beth Israel Deaconess Medical Center, Boston, MA
Moderated ePoster: Saturday, 2:15-4:30 pm, Moderated Session MP-11b

 


 

Key abstract submission guidelines

  • Abstracts must be written in proper and grammatically correct English.
  • There is no limit to the number of abstracts that may be submitted.
  • If previously submitted to a different meeting, an abstract may still be submitted.
  • The submitting author is required to ensure that all co-authors are aware of the abstract content before submission.
  • ASRA does not share information of those who have submitted abstract(s) to institutions or employers. 
  • A presenter is expected to attend the meeting and present the poster. There will be no virtual poster sessions during the meeting.
  • Meeting registration is required at least 3 weeks prior to the meeting in order to be included in the final program.
  • There is no fee to submit an abstract, but there is a $75 fee to submit an ePoster after abstract acceptance.
  • Abstracts must be submitted in quality suitable for publication and with strict adherence with all requirements outlined in the Call for Abstracts.
  • IMPORTANT NOTE: Poster submittals are required for all abstract presentations.

  


 

Submission Content

Abstract Category
  • Scientific Abstracts
    • Acute Pain
    • Chronic Pain
    • Regional Anesthesia
    • Emerging Technology
    • Education
    • Case Series (5 or more patients; patient informed consent required for submission)
  • Medically Challenging Cases: Report of up to 4 cases having a similar presentation; case series of 5 or more patients must be presented as a scientific abstract. Patient informed consent required for submission.
  • Safety/QA/QI Projects: Showcase for Resident quality improvement projects with a focus on chronic pain

Abstract Title

Title is limited to 130 characters including spaces, in sentence format.

Submitting Author Details

The submitting author will receive all communications regarding the abstract and is responsible for informing the other authors, as necessary.

Co-Author(s) Details

Name, contact information, role (author, co-author, presenting author), and display/list order. PLEASE NOTE: if the submitting author is also a co-author, they must be added to this list.

 
Abstract Body

Strictly limited to 1000 words over the following content areas:

  • Introduction
  • Material and Methods (including statement of IRB approval/waiver, IND approval, patient informed consent, etc.)
    • An IRB approval statement must be included along with checking the IRB box under attestations.
    • An investigator cannot him/herself determine if the IRB is needed or not. This can only be done by the IRB. However, if the IRB at your organization has a policy that as long as there is no identifiable patient information in the case report it is IRB exempt, this needs to be stated. So, the wording could read: As the case report is devoid of patient identifiable information, it is exempt from IRB review requirements as per (name of organization) policy.
  • Results / Case Report
  • Discussion
  • References (max. 5 references, not included in 1000 word count)
  • Tables (not included in 1000 word count)
    • Maximum 3 tables of 10 rows x 10 columns
    • File type must be one of the following: .pdf, .jpg, .jpeg, .png
  • Images (not included in 1000 word count)
    • Patient faces must be entirely covered
    • Only figures in JPG format may be uploaded
    • Maximum 2 images
    • Maximum file size of each image is 500 KB
    • Maximum pixel size is 600(w) x 800(h)
    • File type must be one of the following: .pdf, .jpg, .jpeg, .png

Important Considerations
  • No promotional content of a commercial entity may be included (brand/trade/product names, photos, logos, company names, etc.).
  • If necessary for clarity, a trade/product name may be included parenthetically once in the materials and methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
  • Any off-label indications should be clearly marked as such.

 


 

Mandatory Attestations

Conflicts of Interest Disclosure

All submissions require disclosure of financial or other relationships with a commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure must include the company name(s) and nature of relationship (honoraria/expenses, consulting/advisory board, funded research, royalties/patent, stock options, equity position/ownership, employee, other similar relations). Disclosure is required for the submitting author and their spouse/partner over the last 12 months.

 

Institutional Review Board (IRB) and/or Animal Use Committee Approval (select one)
  • IRB and/or animal use committee approval was either obtained or waived for the study. IMPORTANT: abstracts must include this approval/waiver statement under methods and materials.
  • This is a medically challenging case and IRB approval is not mandatory, but I will adhere to the other submission guidelines below. 

 

Patient Informed Consent and Protected Health Information (select all that apply)
  • Patient informed consent was obtained for submission of a case report. IMPORTANT: abstracts must include this consent statement under methods and materials.
  • All patient protected health information has been de-identified; patient faces are entirely covered.
  • This is a scientific abstract with no patient protected health information.

 

Off-Label Drug Use (select all that apply)

  • If my study involves off-label use of drugs placed near the neuraxis, I have obtained an FDA IND and/or I have followed the conditions set forth regarding such experimentation as described within the How to Format Data for Presentation in the Regional Anesthesia and Pain Medicine Journal.
  • If my study involves off-label use of drugs for peripheral nerve block, I have obtained IRB approval.
  • All off-label indications have been clearly indicated as such in the abstract. IMPORTANT: abstracts without this text will be rejected.
  • There are no off-label indications included.

 

Trade Names (select one)
  • No promotional content of a commercial entity is included (brand/trade/product names, photos, logos, company names, etc.).
  • If necessary for clarity, a trade/product name is included parenthetically once in the materials and methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.

 

Copyrighted Material (select one)

  • There are no copyrighted figures, images, or content in my abstract.
  • If copyrighted figures, images or content are contained in my abstract, I have obtained the necessary permission from the copyright owner.

 

Oral Presentation

I would like my abstract to be considered for oral presentation during the moderated poster sessions. (If not, will not be considered for best of meeting awards.)

  • Yes
  • No

 

Research Award

I am a resident or fellow, ASRA member, and would like to be considered for a research award. (ASRA membership is required for award eligibility. Join now.)

  • Yes
  • No

 

Agreement and Submission
  • I reviewed this abstract and all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission; I am aware that it will be published exactly as submitted.
  • I and all others listed as (co-)authors contributed substantively to the writing, review, and work described by this abstract, and further affirm that it was not prepared or written by anyone not listed as an author.
  • I am the sole owner and/or have the rights of all the information and content. The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights. I herewith grant ASRA a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the abstract content.
  • Submission of the abstract constitutes my consent to print and/or electronic publication (e.g. meeting website, program, other promotions, etc.).
  • The submitting author is responsible for informing the other authors about the status of the abstract.
  • It is the author's responsibility to maintain necessary documentation for all attestations (IRB approval/waiver, patient informed consent, copyright, etc.). ASRA is not liable for any issues arising from improper documentation.
  • I understand that my abstract may be immediately rejected and/or removed from any publication if it does not thoroughly comply with all of the above requirements.  

 


 

Review and Grading Process

Abstracts are blind reviewed by at minimum two committee members and are graded using a 3 to 1 scale, with 3 being “must accept and consider for best of meeting”, 2 being “accept” and one 1 being “reject” (reason for rejection to be briefly stated). The ASRA committee performing the review and selecting abstracts for presentation is identified based on the abstract category.

Scientific Abstracts

  • Research Committee
  • Support from the Scientific/Education Committee members with expertise in each field as necessary

Medically Challenging Cases: Scientific/Education Planning Committee

Safety/QA/QI: Program Directors

The ASRA committee review and ranking of abstract submissions does not constitute peer review and should not be interpreted as such. Notification regarding the status (accepted for poster presentation or rejected) will be sent to the abstract author approximately 2 months prior to the meeting. Some submitted abstracts may not be accepted based on their quality or space limitations at the meeting venue.

 

Reviewer Checklist

Reviewers will complete the checklist below to verify that all requirements are integrated into the submitted abstract. Abstracts not complying with all requirements will be automatically rejected. There will be no revision and resubmission period or process.

 

Submission Requirements:

  • The abstract is correctly categorized.
  • The abstract is incorrectly categorized and should be re-categorized (see comments).
  • All abstract content areas are thoroughly completed.
  • Conflicts of interest disclosure and financial support have been declared.  
  • IRB, animal use committee, and/or patient informed consent stated or waived, as necessary.
  • If off-label use, proper approval obtained (IND and/or IRB) and/or follows conditions set forth regarding such experimentation as described within the How to Format Data for Presentation in the Regional Anesthesia and Pain Medicine Journal.
  • Any off-label indications have been clearly marked as such.
  • No promotional content has been used (brand/trade names, logos, ultrasound logos, etc.). If necessary for clarity, a trade/product name is included parenthetically once in the Materials and Methods section, but no more, and not in the abstract title. If more than one company makes the product, all applicable trade names are identified.
  • Copyright permission obtained, if necessary.

 

Scoring:

  • Accept
  • Accept with changes
  • Reject
  • Comments, reasons for rejection, or re-categorization:
    • Incorrectly categorized; Recategorize to Scientific Abstract
    • Incorrectly categorized; Recategorize to Medically Challenging Case
Abstract Scoring Rubric

 


 

Presentation during Meeting

ePoster Fee

ASRA does not charge a fee to submit an abstract. However, $75 will be charged for each abstract actually accepted for ePoster presentation. This payment is non-refundable and partially offsets ASRA’s cost for abstract presentation in the ePoster format. This ePoster fee is generally less expensive than printing a poster; printed posters are not accepted (except for the best of meeting abstracts, see award section below). The ePoster fee will be charged after abstract acceptance and upon online submission of the ePoster.

 

Meeting Pre-Registration

Only abstracts/ePosters by authors who register no later than the ePoster submission deadline will be included in the final program and meeting materials. Meeting registration is refundable according to the meeting cancellation policy.

 

Eligibility

Only authors listed on the submitted abstract may present onsite during the meeting. Investigators who have abstracts approved for presentation but fail to attend the meeting three years in a row will be prohibited from submitting abstracts for the following two years.

 

ePoster Display

All abstracts accepted for poster presentation during the annual meeting will be available onsite each day using ePoster technology. Multiple plasma screens will be available in a clearly identified viewing area. Authors will have 10-15 minutes for scheduled presentation, grouped by category and subcategory as much as possible. The ePosters will not be formally moderated during general viewing hours.

 

Moderated Poster Sessions

Upon submission, authors will have the option to indicate if they would like to be considered for oral presentation during the annual meeting. The maximum number of moderated sessions will be determined by the project management team based on program organization and meeting space; ASRA will provide as many opportunities as possible. Moderated poster sessions will include at least one dedicated session for medically challenging cases. All other sessions will be allocated for presentation of scientific abstracts; these sessions will be structured according to category and subcategory as much as possible. The final number of presentations will be based on the quality of submitted abstracts. Posters will be moderated at various times by various moderators. Each session will be assigned 9 to 12 abstracts. Each presenter will be allocated a maximum of 10 minutes per poster (5 minutes presentation and 5 minutes discussion). 

 


 

Awards

Eligibility 

Membership in ASRA is not required to submit an abstract. However, only abstracts submitted by ASRA members will be considered for the best of meeting awards.

 

Best of Meeting Abstracts (Scientific Abstracts only)

The top 10 highest scoring scientific abstracts that have met all ASRA abstract submission requirements and ASRA membership will be sent to the research committee, which will select 3 best of meeting abstracts. Best of abstract winners benefit from the following:

  • Inclusion in a moderated poster session
  • Invitation to give an oral presentation from the podium (max. 5 minutes with max. 5 slides submitted prior to the meeting and no Q&A)
  • Certificate of achievement (mailed by the ASRA office after the meeting)
  • Poster is tagged in the ePoster system

Best of meeting award recipients must participate in the above presentation activities. If a winner is unable to participate, an alternative award winner will be selected.

 

Resident/Fellow Best of Meeting Abstracts and Research Award

Upon submission, resident/fellow submitters have the option of having their abstract considered for the resident/fellow research award. The top 10 highest scoring resident/fellow scientific abstracts will be sent to the research committee chair who will then select 3 to receive an award. The resident/fellow best of meeting and research award recipients benefit from the following.

  • Inclusion in a moderated poster session
  • Invitation to give an oral presentation from the podium (max. 5 minutes with max. 5 slides submitted prior to the meeting and no Q&A)
  • Certificate of achievement (mailed by the ASRA office after the meeting)
  • Poster is tagged in the ePoster system

Resident/fellow best of meeting and research award recipients must be present to participate in the above presentation activities. If a winner is unable to participate, an alternative award winner will be selected.

 


 

Availability after Meeting

ASRA Society and/or Meeting Websites

Abstracts (as submitted for initial grading) will be included on the ASRA website for three years (starting from 2015). All submitted ePosters will be available online prior to the meeting. Medically challenging cases ePosters are removed three months after the meeting and scientific abstracts after maximum three years.

 

Regional Anesthesia and Pain Medicine Journal (RAPM) Listing (Scientific Abstracts only)

Regional Anesthesia and Pain Medicine (RAPM) is ASRA’s official journal, publishing peer-reviewed scientific and clinical studies. Scientific abstracts presented during the annual meeting are listed in the journal with abstract title, author, and affiliation data only; full abstracts are not included in print, but will be posted on the ASRA website with a link to the RAPM journal website. Medically challenging cases will not be printed in the journal or available on the journal’s website. ePosters will not be printed in the journal.

Close Nav